Showing 2541-2550 of 5771 results for "".
- TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trialhttps://modernod.com/news/tearclear-announces-initiation-of-tc-002-latanoprost-ophthalmic-solution-phase-3-trial/2480617/
- Allotex Announces 3-Year Results of Allogeneic Inlays for the Treatment of Hyperopia and Presbyopiahttps://modernod.com/news/allotex-announces-3-year-results-of-allogeneic-inlays-for-the-treatment-of-hyperopia-and-presbyopia/2480575/Allotex, the maker of
- Envision Conference Announces 2022 In-Person Date, Calls for Submissionshttps://modernod.com/news/envision-conference-announces-2022-in-person-date-calls-for-submissions/2480569/
- Alcon Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europehttps://modernod.com/news/alcon-announces-launch-of-systane-complete-preservative-free-lubricant-eye-drops-in-europe/2480566/
- Ocuphire Announces Enrollment Completion of Phase 3 Nyxol Trial and Initiation of Nyxol Pediatric Trialhttps://modernod.com/news/ocuphire-announces-enrollment-completion-of-phase-3-nyxol-trial-and-enrollment-initiation-of-nyxol-pediatric-trial/2480546/
- Retina Consultants of America Announces Addition of Brown Retina Institutehttps://modernod.com/news/retina-consultants-of-america-announces-addition-of-brown-retina-institute/2480537/Physician management services organization
- ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patients-dosed-in-phase-23-pivotal-trials-of-qr-421a-for-ush2a-mediated-retinitis-pigmentosa/2480522/
- Retina Consultants of America Announces Addition of Mississippi Retina Associateshttps://modernod.com/news/retina-consultants-of-america-announces-addition-of-mississippi-retina-associates/2480508/Retina Consultants of America (RCA) has
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- CXL Ophthalmics Announces Positive Results of Phase 2 Clinical Trial in Epi-On Cross-linking for Keratoconushttps://modernod.com/news/cxl-ophthalmics-announces-positive-results-of-phase-2-clinical-trial-in-epi-on-cross-linking-for-keratoconus/2480447/CXL Ophthalmics released topline results of its landmark phase 2 Trial in transepithelial (Epi-On) cross-linking. Results were summarized as